Web Results

Miglustat

en.wikipedia.org/wiki/Miglustat

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...

Miglustat for treatment of Niemann-Pick C disease: a ... - NCBI

www.ncbi.nlm.nih.gov/pubmed/17689147

Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...

Zavesca - Actelion

www1.actelion.com/en/healthcare-professionals/products/zavesca/index.page

The usual dose of Zavesca® in adult NP-C patients was 200 mg miglustat three times a day, and was adjusted according to body surface area in pediatric NP-C ...

Zavesca (Miglustat): Side Effects, Interactions, Warning, Dosage ...

www.rxlist.com/zavesca-drug.htm

Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...

Zavesca, INN- Miglustat - European Medicines Agency - Europa.eu

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000435/WC500046726.pdf

Each capsule contains 100 mg miglustat. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...

Zavesca, INN- Miglustat - European Medicines Agency

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000435/WC500046721.pdf

Miglustat reduces the biosynthesis of glucosylceramide from ceramide ... Zavesca contains 100 mg of miglustat as active ingredient and it is presented in the ...

Zavesca (miglustat) 100 mg hard capsules - Summary of Product ...

www.medicines.org.uk/emc/medicine/13933

Oct 20, 2015 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SPC) by Actelion Pharmaceuticals UK Ltd.

Evaluation of miglustat as maintenance therapy after enzyme ...

ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-102

Dec 27, 2012 ... Miglustat (Zavesca®; Actelion Pharmaceuticals) is an orally active iminosugar which reversibly inhibits UDP-glucosylceramide synthase – the ...

Miglustat therapy in the French cohort of paediatric patients with ...

ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-36

Jun 7, 2012 ... Miglustat can improve or stabilize neurological manifestations in paediatric patients with the late-infantile and juvenile-onset forms of NP-C.

N-Butyldeoxynojirimycin film (dried in situ) | Sigma-Aldrich

www.sigmaaldrich.com/catalog/product/sigma/b8299?lang=en&region=US

film (dried in situ). Synonym: Miglustat, NB-DNJ. SDS. CAS Number 72599-27-0. Empirical Formula (Hill Notation) C10H21NO4. Molecular Weight 219.28.

More Info

DrugBank: Miglustat

www.drugbank.ca

Miglustat is marketed under the trade name Zavesca. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C) .

Miglustat: MedlinePlus Drug Information

medlineplus.gov

Apr 15, 2016 ... Miglustat: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Miglustat: Indications, Side Effects, Warnings - Drugs.com

www.drugs.com

Easy to read patient leaflet for miglustat. Includes indications, proper use, special instructions, precautions, and possible side effects.